Precision medicine
Also, DeepTek has obtained another 510(k) from the US FDA for its AI solution.
The Japanese manufacturer's new company, established in Delaware, will utilize a cell picking and imaging system to help providers detect and treat diseases.
The company will use the funds to enrich its technology, commercialize its MRD product and continue the development of its multi-cancer early detection offering.
Medicare-focused virtual exercise platform Bold secured $17 million.
The pair will work to further the practice of radiology and patient care using innovation, such as theranostics, AI and digital health platforms.
The multiple sclerosis-focused company will use the funds to speed up the company's commercialization efforts.
The funding comes three months after the company announced it added AI-enabled imaging features and new indications expanding xvision's use to the whole spine.
At HIMSS23, panelists discussed how genomics could improve patient care and the challenges to implementing genetic testing programs.
HIMSS23
Dr. Cecil Lynch, chief medical information officer at Accenture, discusses his upcoming HIMSS23 lecture on genomics' potential impact on patient care and the importance of examining genetic information and its relationship to comorbidities.
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.